GT Biopharma, Inc.
GT Biopharma, Inc. (NASDAQ: GTBP) is trading at $6.88, about ₹660 at today's USD/INR rate, as of 29 Sep 2026, 4:00 PM ET, up 1.10% today. Indian residents can buy GT Biopharma from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$6.71
Today's high
$7.10
52 week low
$4.91
52 week high
$34.25
GTBP opened at $7.08, closed previously at $6.80, and has traded between $4.91 and $34.25 over the past 52 weeks.
About
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Key statistics
Avg. volume
59.12K
Market cap
$8.68M
P/E Ratio
-0.07
Price-to-sales ratio
0.00
Enterprise value
-$2.48M
Free cash flow yield
-298.31%
Debt-to-equity ratio
0.00
Return on equity
-489.96%
ROIC
-214.65%
Beta
0.91
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$0.00
Earnings per share
-$156.25
Free cash flow
-$12.91M
Net profit margin
0.00%
Gross margin
0.00%
EBITDA
-$28.23M
Revenue growth
0.00%
Similar securities
This is not an investment recommendation
How to buy GT Biopharma from India
Indian residents can buy GT Biopharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for GT Biopharma and place an order
Find GT Biopharma by name or by its ticker, GTBP, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. GT Biopharma trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your GT Biopharma position in USD and INR. GT Biopharma pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in GT Biopharma from India
Trading and taxes when buying GT Biopharma from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneGT Biopharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy GT Biopharma stock?
Yes. GT Biopharma (GTBP) has been listed on NASDAQ since 2018, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one GT Biopharma share cost in rupees?
One GT Biopharma share is $6.88 — about ₹660 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the GT Biopharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying GT Biopharma from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of GT Biopharma?
Yes. One GT Biopharma share is $6.88, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in GT Biopharma.
How are gains on GT Biopharma shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the GT Biopharma price. Paasa issues a capital-gains statement for your return.
Does GT Biopharma pay a dividend?
No. GT Biopharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade GT Biopharma from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on GT Biopharma shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare GT Biopharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your GT Biopharma holding, its cost and its closing value.
How do I sell GT Biopharma and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.